Karla Menjivar
Family · Los Angeles, CANPI 1205155447
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 73.9% of it on its own, with 32 other manufacturers making up the rest. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $55.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Bayer$1K
- AstraZeneca$1K
- Calliditas Therapeutics US Inc.$613
- Novo Nordisk$538
- ANI Pharmaceuticals, Inc.$491
- plus $5K from 27 others
What the payments were for
- Consulting fees$3,1979%
- Speaking & faculty fees$13,50037%
- Travel & lodging$5,80316%
- Food & beverage$13,83938%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 226 | $26,949 |
| Bayer | 59 | $1,256 |
| AstraZeneca | 36 | $1,218 |
| Calliditas Therapeutics US Inc. | 28 | $613 |
| Novo Nordisk | 27 | $538 |
| ANI Pharmaceuticals, Inc. | 25 | $491 |
| Fresenius USA Marketing, Inc. | 31 | $482 |
| Vifor Pharma, Inc. | 21 | $453 |
| Lilly USA, LLC | 20 | $426 |
| Mallinckrodt Hospital Products Inc. | 18 | $424 |
| Akebia Therapeutics Inc | 19 | $404 |
| OPKO Pharmaceuticals, LLC | 24 | $403 |
| Novartis | 24 | $388 |
| Sanofi | 11 | $383 |
| Ardelyx, Inc. | 14 | $316 |
| Boehringer Ingelheim | 13 | $302 |
| Dexcom, Inc. | 10 | $276 |
| Travere Therapeutics, Inc. | 17 | $215 |
| Xeris Pharmaceuticals, Inc. | 9 | $197 |
| Aurinia Pharma U.S., Inc. | 6 | $149 |
| Esperion Therapeutics, Inc. | 4 | $96 |
| Sanofi-aventis U.S. LLC | 4 | $88 |
| Apellis Pharmaceuticals, Inc. | 2 | $60 |
| Mannkind Corporation | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Seqirus USA Inc | 2 | $41 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Pfizer | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,458 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 669 | $423,533 |
| FarxigaDapagliflozin Propanediol | 374 | $228,429 |
| RybelsusSemaglutide | 218 | $209,080 |
| LokelmaSodium Zirconium Cyclosilicate | 214 | $180,286 |
| AuryxiaFerric Citrate | 118 | $152,944 |
| Repatha SureclickEvolocumab | 267 | $140,360 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 166 | $137,630 |
| JardianceEmpagliflozin | 196 | $119,601 |
| VeltassaPatiromer Calcium Sorbitex | 92 | $87,141 |
| OzempicSemaglutide | 75 | $70,693 |
| DapagliflozinDapagliflozin Propanediol | 126 | $62,722 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,215 |
| ProcritEpoetin Alfa | 73 | $55,819 |
| EpogenEpoetin Alfa | 131 | $54,077 |
| MounjaroTirzepatide | 51 | $50,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $1,256 | $423,533669 claims |
| AstraZenecaFarxiga, Lokelma | $1,218 | $408,715588 claims |
| Novo NordiskRybelsus, Ozempic | $538 | $279,773293 claims |
| Akebia Therapeutics IncAuryxia | $404 | $152,944118 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $88 | $137,630166 claims |
| Boehringer IngelheimJardiance | $302 | $119,601196 claims |
| Lilly USA, LLCMounjaro, Trulicity | $426 | $80,35185 claims |
| AmgenEpogen | $26,949 | $54,077131 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $403 | $27,99025 claims |
| PfizerEliquis | $26 | $22,06733 claims |
| Esperion Therapeutics, Inc.Nexlizet | $96 | $10,13122 claims |
| NovartisEntresto | $388 | $8,04013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Phoebedel ReyesLos Angeles$26K
- Ayana ElliottLos Angeles$25K
- Lori RobertsonChino Hills$475K
- Lisa HigginsHanford$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.